Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility

被引：29

作者：

Van Baelen, Kurt ^{[1
]}

Van Eygen, Veerle ^{[1
]}

Rondelez, Evelien ^{[1
]}

Stuyver, Lieven J. ^{[1
]}

机构：

[1] Virco BVBA, B-2800 Mechelen, Belgium

来源：

AIDS | 2008年 / 22卷 / 14期

关键词：

D O I：

10.1097/QAD.0b013e32830f9703

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The contribution of clade-specific polymorphisms in the HIV-1 integrase gene towards integrase inhibitor phenotypic susceptibility was tested on 137 clinical isolates, of which 60 were non-clade B strains. Control Q148R mutant virus showed fold change values of 17.85 +/- 2.77 and 88.94 +/- 9.02 for raltegravir and elvitegravir, respectively, whereas the average fold change for the clinical samples was 0.91 +/- 0.40, and 0.84 +/- 0.37. Phenotypic testing proved that clade-specific integrase polymorphisms do not contribute to reduced susceptibility towards integrase inhibitors.

引用

页码：1877 / 1880

页数：4

共 25 条

[1] DOMAINS OF THE INTEGRASE PROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RESPONSIBLE FOR POLYNUCLEOTIDYL TRANSFER AND ZINC-BINDING [J].